Long lasting remission by rituximab in a patient with primary cold agglutinin autoimmune haemolytic anaemia
作者： Marjana Glaser , Andrej Glaser , Marjan Skalicky
DOI: 10.1007/S00508-011-0060-6
关键词:
摘要: A 76-year-old female patient with cold agglutinin autoimmune haemolytic anaemia (CAHA) is presented. The haemolysis worsened during infection. Earlier, the underwent an unsuccessful treatment steroids, chlorambucil , folic acid and heated erythrocyte transfusion. We treated her monoclonal anti-CD20 antibody Rituximab (RTX) weekly for four consecutive weeks. After three cycles, signs of slowly disappeared haemoglobin completely normalized. continued maintenance RTX every third month 2 years. in complete remission. This case report emphasizes importance use as a therapy immune cytopenia. Patients CAHA usually fail to respond standard treatment. Since very rare condition, only some reports studies reported on positive effects RTX. Although expensive, has many advantages, such quick long-term efficiency few side effects.
springer.com
sci-hub.se 参考文章(17)
Dolors Colomer, Elias Campo, Itziar Salaverria, Patricia Perez-Galan, Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives Haematologica. ,vol. 91, pp. 11- 16 ,(2006) , 10.3324/%X
Yoshinori Shirafuji, Yoshinobu Maeda, Keiji Iwatsuki, Cold agglutinin-induced acrocyanosis in a patient with subclinical chronic lymphocytic leukemia; a beneficial response to rituximab European Journal of Dermatology. ,vol. 20, pp. 394- 396 ,(2010) , 10.1684/EJD.2010.0908
Peter Valent, Klaus Lechner, Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wiener Klinische Wochenschrift. ,vol. 120, pp. 136- 151 ,(2008) , 10.1007/S00508-008-0945-1
Pasquale Niscola, Paolo de Fabritiis, Laura Scaramucci, Alessio Perrotti, Massimiliano Palombi, Malgorzata Monika Trawinska, Marco Giovannini, Long-lasting remission induced by rituximab in two cases of refractory autoimmune haemolytic anaemia due to cold agglutinins Vox Sanguinis. ,vol. 7, pp. 235- 236 ,(2009) , 10.2450/2008.0066-08
Paola Masolini, Renato Fanin, Mario Regazzi, Alessandra Sperotto, Salvatore De Vita, Isabella Iacona, Simonetta Prosdocimo, Michele Baccarani, Francesco Zaja, Francesca Patriarca, Domenico Russo, B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. ,vol. 87, pp. 189- 195 ,(2002) , 10.3324/%X
Claudia Schöllkopf, Lars Kjeldsen, Ole Weiss Bjerrum, Hans Torben Mourits-Andersen, Johan Lanng Nielsen, Bjarne Egelund Christensen, Bjarne Anker Jensen, Bjarne Bach Pedersen, Ellen Birkerod Taaning, Tobias Wirenfeldt Klausen, Henrik Birgens, Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients Leukemia & Lymphoma. ,vol. 47, pp. 253- 260 ,(2006) , 10.1080/10428190500286481
Sigbjørn Berentsen, Elling Ulvestad, Bjørn Tore Gjertsen, Henrik Hjorth-Hansen, Ruth Langholm, Håvar Knutsen, Waleed Ghanima, Fuad Victor Shammas, Geir E Tjønnfjord, Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients Blood. ,vol. 103, pp. 2925- 2928 ,(2004) , 10.1182/BLOOD-2003-10-3597
S. Berentsen, Rituximab for the treatment of autoimmune cytopenias Haematologica. ,vol. 92, pp. 1589- 1596 ,(2007) , 10.3324/HAEMATOL.11312
Ronald P Taylor, Margaret A Lindorfer, Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Current Opinion in Immunology. ,vol. 20, pp. 444- 449 ,(2008) , 10.1016/J.COI.2008.05.011
Bernadette Garvey, Rituximab in the treatment of autoimmune haematological disorders British Journal of Haematology. ,vol. 141, pp. 149- 169 ,(2008) , 10.1111/J.1365-2141.2008.07054.X